PhotoPharmics is a leading brand in the field of specialized phototherapy, offering innovative treatments for neurological and neuropsychiatric disorders. Their breakthrough technology, Celeste Light for PD, is designed specifically for patients with Parkinson's disease. With a strong focus on research and development, PhotoPharmics has successfully completed a phase 2 trial, demonstrating significant improvements in motor and non-motor symptoms, as well as overall quality of life for Parkinson's patients.

Now, they are excitedly moving forward with their phase 3/pivotal trial, which will enroll 300 patients and aim to provide the necessary data for market clearance. This trial has received concurrence from the FDA and will be conducted by the renowned clinical trial center, CHeT at the University of Rochester. Through their dedication to advancing non-drug treatments, PhotoPharmics is committed to revolutionizing the field of neurodegenerative and neuropsychiatric disorders, ultimately providing novel, safe, and effective treatments for those in need